Results 141 to 150 of about 45,933 (222)

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

TP53 Mutation Heterogeneity Refines Prognostic Stratification in IDH‐Wildtype Glioma

MedComm, Volume 7, Issue 10, October 2026.
This study reveals that TP53 mutations in IDH‐wildtype gliomas are prognostically heterogeneous. A variant allele frequency (VAF) ≥10% identifies a high‑risk subgroup, and mutations located in the β‑strand region of the DNA‑binding domain confer the poorest outcomes.
Kuilin Liao, Zhi Ye, Songtao Qi, Chang Xu, Yudi Huang, Zhiyong Li, Guozhong Yi, Yuou Qin, Qiuming Pan, Guiling Liu, Chao Chen, Zhuoyang Chen, Hongrui Li, Junxi Wang, Xi'an Zhang, Guanglong Huang, Shanqiang Qu   +16 more
wiley   +1 more source

KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine

MedComm, Volume 7, Issue 10, October 2026.
KRAS‐mutant cancers are therapeutically shaped by both allele identity and tumor context. Direct KRAS inhibition has achieved the greatest clinical success in KRAS G12C‐mutant NSCLC, whereas colorectal cancer often requires EGFR cotargeting and pancreatic cancer remains constrained by stromal and metabolic barriers. Shared resistance mechanisms include
Jiaying Cai, Yimin Wu, Xing Jia, Li Yang, Wenjun Yang, Weishan Lu, Zhiye Huang, Yang Pan, Zixuan Fei, Junnan Ru, Jiazheng Zhao, Jue Shen, Taobo Luo, Da Chen, Haihong Yu, Haihan Deng, Jian Zeng, Wenmei Jiang, Leilei Wu   +18 more
wiley   +1 more source

Phytochemicals as Multitarget Therapeutics in Pancreatic Cancer: Mechanisms, Clinical Evidence, and Translational Challenges

Phytotherapy Research, Volume 40, Issue 10, Page 5973-5987, October 2026.
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is aggressive and often diagnosed late, making treatment challenging. This review highlights the potential of phytochemicals, such as curcumin and quercetin, as multitarget agents that influence key carcinogenic pathways. These compounds exhibit anticancer effects by inhibiting processes
Md. Rezaul Islam, Abdur Rauf, F. M. Shourav, Hanan A. Ogaly, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Kamala Badalova, Marcello Iriti   +7 more
wiley   +1 more source

Nephrotic Range Proteinuria Due to Everolimus in a Renal Transplant Recipient

Turkish Journal of Nephrology, 2019
Survival of transplant recipients strongly depends on the success of the immunosuppressive regimen. Many immunosuppressive drugs such as calcineurin inhibitors (CNIs) and purine biosynthesis inhibitors (mycophenolic acids) are used after renal ...
Garip ŞAHİN, N. Şule YAŞAR, Evrim ÇİFTÇİ, Ahmet Uğur YALÇIN, Haluk KİPER   +4 more
doaj  

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2619-2635, October 2026.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials

Clinical Transplantation, Volume 40, Issue 10, October 2026.
ABSTRACT Left ventricular hypertrophy in heart transplant recipients has been attributed to the use of calcineurin inhibitors. We assessed left ventricular mass across treatment arms in 83 heart transplant recipients in the Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE), and in 75 ...
Klaus Murbraech, Feben Tecklzig, Richard John Massey, Einar Gude, Finn Gustafsson, Hans Eiskjær, Kristjan Karason, Göran Rådegran, Arne K. Andreassen, Lars Gullestad, Kaspar Broch   +10 more
wiley   +1 more source

The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view

, 2014
Oscar D Sanchez, Kazuyuki Yahagi, Tobias Koppara, Renu Virmani, Michael Joner CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide.
Koppara T, Joner M, Virmani R, Yahagi K, Sanchez OD   +4 more
core  

Effects of Timing of Everolimus Transition on Renal Outcomes in Liver Transplant Recipients. [PDF]

J Transplant
Leick M, Belleau H, McCashland T.
europepmc   +1 more source

Cannabidiol in Adults With Lennox–Gastaut Syndrome: Real‐World Experience

European Journal of Neurology, Volume 33, Issue 10, October 2026.
Cannabidiol showed sustained effectiveness and good tolerability in adults with LGS, with high retention over a median follow‐up of 41 months. Treatment was associated with improvement in seizure burden, increased seizure‐free days, fewer seizure‐related hospital admissions, and caregiver‐reported improvement in cognitive and behavioural functioning ...
Pyae Aung, Debbie Miller, Emily Sewell, Laura Mantoan Ritter, Evangelia Theochari, Ioannis Stavropoulos, Robert Delamont, Mark P. Richardson, Joel S. Winston, Lina Nashef   +9 more
wiley   +1 more source